Related Experiment Video

Updated: Mar 8, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.0K

Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade

Vanessa Souza-Mello1

  • 1Vanessa Souza-Mello, Biomedical Centre, Institute of Biology, Department of Anatomy, State University of Rio de Janeiro, Rio de Janeiro 20551-030, Brazil.

World Journal of Hepatology
|February 2, 2017
PubMed

Insights

Angiotensin receptor blockers (ARBs) help manage obesity-related issues like insulin resistance and fatty liver disease. They promote weight loss and reduce liver fibrosis, especially when combined with PPAR-alpha activation.

Area of Science:

  • Metabolic Syndrome and Liver Disease
  • Pharmacology of the Renin-Angiotensin System

Background:

  • Obesity is linked to increased renin-angiotensin system (RAS) activity, contributing to metabolic dysfunction and non-alcoholic fatty liver disease (NAFLD).
  • Pharmacological targeting of RAS components offers potential therapeutic strategies for obesity comorbidities.

Discussion:

  • Angiotensin-converting enzyme inhibitors and ARBs show promise in improving hepatic steatosis and fibrosis.
  • ARBs demonstrate efficacy in reducing body mass, improving insulin sensitivity, and modulating inflammatory markers.
  • Combined therapy with ARBs and peroxisome proliferator-activated receptor (PPAR)-alpha activation offers complete resolution of fatty liver.

Key Insights:

  • AT1R blockade by ARBs may indirectly upregulate the MAS receptor, influencing therapeutic outcomes.
  • ARBs improve insulin sensitivity and reduce hepatic steatosis, offering a dual benefit for metabolic health.
  • The interplay between ARB, PPAR activation, and the ACE2-angiotensin (ANG) (1-7)-MAS receptor axis warrants further investigation.

Outlook:

  • Further research is needed to elucidate the mechanisms underlying the synergistic effects of ARBs and PPAR activation.
  • Exploring the ACE2-ANG (1-7)-MAS receptor pathway in conjunction with AT1R blockade could reveal novel therapeutic targets.
  • Investigating ARBs as a therapeutic strategy for obesity-induced metabolic impairments and NAFLD is a promising avenue.
Keywords:
Angiotensin receptor blockersInsulin resistanceMAS receptorNon-alcoholic fatty liver diseaseRenin-angiotensin system

More Related Videos

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds12:32

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

Published on: January 23, 2018

13.0K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
5.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
821
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
769
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
991